Company Filing History:
Years Active: 2022
Title: Mark Anthony Febbraio: Innovator in NASH Treatment
Introduction
Mark Anthony Febbraio is a prominent inventor based in New South Wales, Australia. He has made significant contributions to the field of medical research, particularly in the treatment of non-alcoholic steatohepatitis (NASH). His innovative approaches aim to address critical health issues associated with this condition.
Latest Patents
Febbraio holds a patent for "Methods for treating NASH and for preventing NASH-induced HCC." This patent discloses methods of treating NASH and preventing NASH-induced hepatocellular carcinoma (HCC). The methods include administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), either alone or in combination with an inhibitor of the interleukin-6 receptor transsignaling response, particularly gp130Fc. He has 1 patent to his name.
Career Highlights
Febbraio is associated with N-gene Research Laboratories, Inc., where he continues to advance his research and innovations. His work focuses on developing effective treatments for complex health conditions, showcasing his dedication to improving patient outcomes.
Collaborations
He collaborates with notable professionals in the field, including his coworker József Mandl. Their combined expertise contributes to the advancement of research in NASH and related health issues.
Conclusion
Mark Anthony Febbraio is a key figure in the innovation of treatments for NASH, with a focus on improving health outcomes through his patented methods. His contributions to medical research are invaluable and reflect his commitment to addressing significant health challenges.